This study investigated the acute (within 24 hours) effect of the first administration of luseogliflozin, an SGLT2 inhibitor, on nocturnal basal GV in patients with type 2 diabetes mellitus. The gene discussed is SLC5A2; the disease is diabetes mellitus.